文献速递血脂与心血管预防

长期获益策略与标准风险策略在初级预防中他汀准入的比较

A Long-term Benefit Approach vs Standard Risk-Based Approaches for Statin Eligibility in Primary Prevention.
PubMed 文献 · JAMA Cardiol · 2018-01-01

结果显示30年获益策略使17.5%个体符合他汀准入,识别出更年轻、女性更多、LDL-C更高的人群,且可预防事件最多。

要点

  • 30年获益策略(ARR≥15%)使17.5%个体符合他汀准入,高于10年风险策略的9.5%和10年获益策略的13.0%。
  • 仅符合30年ARR≥15%者更年轻(平均50岁)、女性更多(43%)、LDL-C更高(149 mg/dL),10年风险较低(4.7%)。

核心结论

  • 长期获益策略可识别近1/6个体具有高预期长期他汀获益,需治疗人数少于7。
  • 该策略识别出更年轻、LDL-C更高且当前指南不推荐治疗的个体,可能更优。

研究设计与样本

  • 横断面分析,使用NHANES 2009-2010、2011-2012、2013-2014数据。

主要发现

  • 基于7.5% 10年心血管风险的他汀准入率为9.5%;基于2.3% 10年ARR为13.0%;基于15% 30年ARR为17.5%。
  • 仅符合30年ARR≥15%者平均年龄50岁(95%CI 48-52),女性占43%(95%CI 26%-59%),平均10年风险4.7%(95%CI 4.4%-5.1%),平均LDL-C 149 mg/dL(95%CI 142-155)。
  • 符合10年ARR≥2.3%者平均年龄56岁(95%CI 54-57),女性占22%(95%CI 10%-34%),平均10年风险9.3%(95%CI 8.3%-10.2%),平均LDL-C 110 mg/dL(95%CI 103-118)。

关键数值与推荐

  • 他汀准入阈值:10年风险≥7.5%、10年ARR≥2.3%、30年ARR≥15%。
  • 30年获益策略需治疗人数少于7。

临床怎么用

  • 在初级预防中可考虑采用30年获益策略筛选他汀治疗对象,尤其是年轻、LDL-C较高但10年风险较低者。
  • 该策略可能避免治疗预期获益低的个体,同时识别更多可预防事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: A 10-year benefit-based approach to statin therapy in primary prevention includes younger individuals with higher low-density lipoprotein cholesterol (LDL-C) and prevents more cardiovascular events than a risk-based approach. However, a 10-year treatment duration likely underestimates the expected benefits of statins. OBJECTIVE: To model the impact of a 30-year benefit approach to select individuals for statin therapy. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional analysis of the National Health and Nutrition Survey (NHANES) data set included samples of the US population from the 2009-2010, 2011-2012, and 2013-2014 data collection cycles. Individuals between 40 to 60 years old who did not have atherosclerotic cardiovascular disease, diabetes, or LDL-C levels greater than 190 mg/dL and who were not taking statins were included. Data analysis took place from November 2017 to August 2018. EXPOSURES: We calculated 10-year risk of atherosclerotic cardiovascular disease and 10-year and 30-year absolute risk reduction (10-year ARR and 30-year ARR) of atherosclerotic cardiovascular disease for each individual. MAIN OUTCOMES AND MEASURES: Number of individuals meeting eligibility for statins based on 10-year (atherosclerotic) cardiovascular disease risk, 10-year ARR, or 30-year ARR. RESULTS: A total of 1688 individuals were included, representing 56.6 million US individuals. Statin eligibility based on 7.5% CVR10 was 9.5%; based on 2.3% 10-year ARR, 13.0%, and based on 15% 30-year ARR, 17.5%. The 10-year risk, 10-year benefit, and 30-year benefit approaches all led to similar acceptable mean absolute risk reductions at 30 years, with the benefit-based approaches better able to avoid treatment of individuals with low expected benefit. Individuals who met statin eligibility based solely on the 30-year ARR threshold of 15% or greater were younger (mean age, 50 [95% CI, 48-52] years) and more likely to be women (43% [95% CI, 26%-59%]) than those recommended with a 10-year ARR threshold of 2.3% or greater (mean age, 56 [95% CI, 54-57] years; 22% [95% CI, 10%-34%] women). This group also had lower 10-year risk (mean risk, 4.7% [95% CI, 4.4%-5.1%]) and higher LDL-C levels (mean level, 149 mg/dL [95% CI, 142-155 mg/dL]) than those recommended with a 10-year ARR threshold of 2.3% or greater (mean risk, 9.3% [95% CI, 8.3%-10.2%]; mean LDL-C levels, 110 [103-118] mg/dL). Preventable atherosclerotic cardiovascular disease events in 10 and 30 years were highest using the 30-year benefit approach (296 000 at 10 years and 2.03 million at 30 years) and lowest based on 10-year risk (204 000 at 10 years and 1.18 million at 30 years). CONCLUSIONS AND RELEVANCE: A long-term benefit approach to statin eligibility identifies nearly 1 in 6 individuals as having a high degree of expected long-term benefit of statins, with a number needed to treat of less than 7. This approach identifies younger individuals with higher LDL-C levels who would not be currently recommended for treatment and may provide a more optimal approach for determining statin eligibility in primary prevention.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Thanassoulis G, Sniderman AD, Pencina MJ, et al. A Long-term Benefit Approach vs Standard Risk-Based Approaches for Statin Eligibility in Primary Prevention. JAMA Cardiol. 2018. PMID: 30422172. doi:10.1001/jamacardio.2018.3476

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。